Autoimmune Monoclonal Antibody Market Report 2026

Autoimmune Monoclonal Antibody Market Overview

• Autoimmune Monoclonal Antibody market size has reached to $70.86 billion in 2025 • Expected to grow to $104.57 billion in 2030 at a compound annual growth rate (CAGR) of 8.1% • Growth Driver: Increasing Demand For Biologics Is Fueling The Market Growth Due To Their Effectiveness In Treating Complex Autoimmune Conditions • Market Trend: Innovation In Biosimilar Development Enhancing Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Autoimmune Monoclonal Antibody Market?

Autoimmune monoclonal antibodies are lab-made proteins designed to target specific components of the immune system involved in autoimmune diseases. These antibodies help regulate or block abnormal immune responses that mistakenly attack the body’s own tissues. Their main purpose is to reduce inflammation and prevent the immune system from attacking the body’s own tissues, thereby minimizing damage and maintaining normal physiological function. The main types of autoimmune monoclonal antibody include Immunoglobulin G (IgG) monoclonal antibodies, Immunoglobulin M (IgM) monoclonal antibodies, chimeric monoclonal antibodies, and fully human monoclonal antibodies. IgG monoclonal antibodies are lab-engineered proteins designed to specifically target and bind to molecules in the body, regulating immune responses to provide precise and prolonged therapeutic effects in autoimmune treatments. These antibodies can be administered through various routes, including subcutaneous, intravenous, and intramuscular. They are used to treat conditions such as rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, psoriasis, and inflammatory bowel disease. Distribution channels for these antibodies include hospital pharmacies, online pharmacies, and retail pharmacies. The primary end users of these therapies are hospitals, outpatient clinics, homecare settings, and research institutions.

What Is The Autoimmune Monoclonal Antibody Market Growth Forecast?

The autoimmune monoclonal antibody market size is expected to see strong growth in the next few years. It will grow to $104.57 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to precision immunology advancement, biosimilar penetration, long-acting antibody development, outpatient biologic administration, personalized autoimmune therapy. Major trends in the forecast period include increased adoption of targeted biologic therapies, expansion of fully human antibody development, rising use in chronic autoimmune conditions, growth in subcutaneous administration preference, focus on long-term disease control.

What Is The Driver Of The Autoimmune Monoclonal Antibody Market?

The increasing demand for biologics is expected to propel the growth of the autoimmune monoclonal antibody market going forward. Biologics refers to a category of medical products derived from living organisms or their components, used in the treatment, prevention, or diagnosis of diseases. The increasing demand for biologics is primarily driven by their ability to effectively treat complex diseases, such as cancer, autoimmune disorders, and genetic conditions, where traditional therapies may be less effective. Autoimmune monoclonal antibody enhances biologic therapies by providing targeted immune modulation, making them effective for managing overactive immune responses. They reduce the need for broad immunosuppressants by offering precise treatment, improving patient outcomes and minimizing side effects. For instance, in June 2024, according to the Cardinal Health Inc., a US-based healthcare company, there are 40 Food and Drug Administration (FDA) approved biosimilar products in 2023, 25 of which are commercially available in the US market, an increase from 33 biosimilar products in 2022. Therefore, the increasing the demand for biologics is driving the growth of the autoimmune monoclonal antibody industry.

Key Players In The Global Autoimmune Monoclonal Antibody Market

Major companies operating in the autoimmune monoclonal antibody market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., UCB S.A., Genmab A/S, Zymeworks Inc., Xencor Inc., Immutep Limited, Cue Biopharma Inc., Santa Ana Bio Inc.

Global Autoimmune Monoclonal Antibody Market Trends and Insights

Major companies operating in autoimmune monoclonal antibody are focusing on developing innovative solutions, such as biosimilar development to enhance safety, efficacy, and quality. Biosimilar development is the process of creating highly similar, safe, and effective biological products to existing approved biologics, using advanced biotechnology, rigorous analytical testing, and clinical studies to demonstrate comparable quality, efficacy, and safety for regulatory approval. For instance, in February 2025, Biocon Biologics Limited, an India-based biopharmaceutical company, launched YESINTEK, a biosimilar that treats autoimmune diseases such as Crohn’s disease, ulcerative colitis, and psoriasis, by targeting and inhibiting the activity of interleukin-12 and interleukin-23 to reduce inflammation and regulate the immune response. Yesintek by mimicking the reference product stelara, supports long-term disease management while increasing patient access to biologic therapies.

What Are Latest Mergers And Acquisitions In The Autoimmune Monoclonal Antibody Market?

In June 2023, Merck & Co, a US-based pharmaceutical company, acquired Prometheus Biosciences, Inc. for approximately $10.8 billion. With this acquisition, Merck aims to accelerate precision medicine development in immunology by leveraging Prometheus’ technology, data analytics, and the TL1A-targeting candidate PRA023 to address unmet needs in immune-mediated diseases. Prometheus Biosciences Inc. is a US-based biotechnology company specializing in providing autoimmune monoclonal antibody.

What Defines the Autoimmune Monoclonal Antibody Market?

The autoimmune monoclonal antibody market consists of sales of adalimumab (humira), etanercept (enbrel), infliximab (remicade), rituximab (rituxan), tocilizumab (actemra), belimumab (benlysta), and secukinumab (cosentyx). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Autoimmune Monoclonal Antibody Market Report 2026?

The autoimmune monoclonal antibody market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the autoimmune monoclonal antibody industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.